Kaftrio

Tezacaftor/elexacaftor/ivacaftor, the active ingredient in Kaftrio, is a CFTR modulator presented as a elexacaftor 100 mg / tezacaftor 50 mg / ivacaftor 75 mg oral tablet for oral use. It is indicated for the treatment of cystic fibrosis in patients aged 12 years and older who carry at least one F508del mutation, improving the function of the defective CFTR protein.

GNH USA supplies Kaftrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards.

Kaftrio is a CFTR modulator used in the management of cystic fibrosis, a genetic disorder affecting chloride transport. - Cystic fibrosis (patients ≥12 years with at least one F508del mutation): improves lung function and reduces pulmonary exacerbations. - Cystic fibrosis (patients ≥12 years with two F508del mutations): provides greater clinical benefit compared with single‑mutation therapy. - Cystic fibrosis (patients ≥12 years with one F508del and a minimal‑function mutation): expands treatment options for this genotype subgroup.

Kaftrio may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: may be watery and intermittent. - Nausea: often transient after dosing. - Abdominal pain: cramp‑like discomfort. - Rash: skin erythema or pruritus. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Hepatitis: significant liver injury requiring monitoring. - Cataracts or retinal changes: visual disturbances reported. - Severe allergic reactions: anaphylaxis or angioedema. - Dyspnea: worsening respiratory symptoms. - Elevated bilirubin: possible jaundice.

Before initiating Kaftrio, several safety considerations should be observed. - Liver monitoring: obtain baseline liver function tests and repeat periodically. - Drug interactions: review concomitant CYP3A4 substrates and inhibitors. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Respiratory status: monitor for any worsening of pulmonary symptoms. - Adherence: take tablets with a fat‑containing meal to enhance absorption. - Store at ambient temperature: keep below 25 °C, in the original pack, and protect from moisture.

Kaftrio interacts with several medications that affect its metabolism and absorption.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and risk of toxicity. - High‑dose statins (e.g., simvastatin >20 mg): increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise plasma levels. - Antacids containing aluminum or magnesium: may decrease absorption if taken concurrently. - Oral contraceptives: potential reduction in efficacy; consider alternative contraception.